End of Year Review in CRC: Exploring Emerging Treatment Options and Clinical Insights on the Future Landscape

News
Video

Cathy Eng, M, FACP, FASCO, presents a comprehensive End-of-Year Review in Colorectal Cancer (CRC), delving into the exploration of emerging treatment options and clinical insights on the future landscape. This insightful review includes a focus on the recent approval of fruquintinib and important updates on target therapies for HER2+, BRAF V600E-Mutant, and KRAS-mutant CRC, as well as an interactive Q&A segment.

Related Videos
Pashtoon Murtaza Kasi, MD, MS
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
A panel of 4 experts on colorectal cancer
Heinz-Josef Lenz, MD, FACP
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Scott Kopetz, MD, PhD, FACP
A panel of 4 experts on colorectal cancer
Related Content
FDA

FDA to Hold End-of-Phase 2 Meeting for Botensilimab Plus Balstilimab in R/R mCRC

May 16th 2024
Article
John H. Strickler, MD

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023
Podcast
FDA

FDA Approves Noninvasive Stool RNA Screening Test for CRC

May 7th 2024
Article
Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022
Podcast
Awny Farajallah, MD, of Takeda

Fruquintinib Receives Positive CHMP Opinion for Previously Treated mCRC

April 26th 2024
Article
Guido Baechler

Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection

April 25th 2024
Article